Managing Blood Pressure in Type 2 Diabetes and Kidney Disease

One hundred million people across Europe live with chronic kidney disease, facing heavily elevated cardiovascular risks, ad-hoc-news.de reported.

Key Clinical Takeaways:

• New guidelines from the European Society of Cardiology and the European Renal Association target an estimated 100 million chronic kidney disease patients across Europe.
• Data from the OPTIMAL-DIABETES trial show that intensive blood pressure reduction under 120 mmHg did not significantly lower major cardiovascular events in type 2 diabetes patients compared to standard targets, while increasing renal events.
• German epidemiological data from the Robert Koch Institute show over 30 percent of adults suffer from hypertension, with roughly 30 percent remaining undiagnosed.

A June 2026 guideline published jointly by the American Heart Association, the American College of Cardiology, the American Diabetes Association, and the American Society of Nephrology expanded prior recommendations to demand a strictly interdisciplinary approach for cardiovascular-kidney-metabolic syndrome, ad-hoc-news.de reported.

European medical societies followed on November 7, 2026, with a joint European Society of Cardiology and European Renal Association guideline emphasizing the massive continental burden of renal dysfunction, ad-hoc-news.de reported.

Task-force chair Kevin Damman noted that kidney disorders and cardiovascular diseases accelerate each other, ad-hoc-news.de reported.

The framework introduces the “STAMP on CKD” concept, mandating systematic screening, structured risk evaluation, and coordinated use of RAS inhibitors, SGLT2 inhibitors, and statins, ad-hoc-news.de reported.

To evaluate treatment thresholds, the randomized OPTIMAL-DIABETES study examined 9,476 adults aged 50 and older with type 2 diabetes and systolic blood pressures between 130 and 180 mmHg across 33 Brazilian centers, ad-hoc-news.de reported.

Led by Karla Santo at the Hospital Israelita Albert Einstein in São Paulo, patient recruitment ran from August 2019 to October 2021, ad-hoc-news.de reported.

Participants had a baseline average blood pressure of 146/80 mmHg, with 28.5 percent exhibiting prior cardiovascular disease and 22.6 percent presenting with chronic kidney disease, ad-hoc-news.de reported.

Researchers compared an intensive systolic blood pressure target under 120 mmHg against a standard target under 140 mmHg, achieving average values of 122 mmHg versus 135 mmHg after three months, ad-hoc-news.de reported.

Over a median four-year follow-up, a primary cardiovascular endpoint occurred in 286 individuals (6.0 percent) in the intensive group and 315 individuals (6.7 percent) in the standard group, yielding a statistically non-significant difference of roughly 10 percent, ad-hoc-news.de reported.

Conversely, intensive lowering triggered more renal events, documented in 270 individuals (5.7 percent) versus 175 individuals (3.7 percent), driven primarily by a decline in the estimated glomerular filtration rate, ad-hoc-news.de reported.

Santo urged individualized therapeutic adjustments based on these outcomes, while Berwanger cautioned that intensive blood pressure reduction yields smaller benefits in type 2 diabetes patients than in non-diabetic populations, ad-hoc-news.de reported.

A sister trial, OPTIMAL-STROKE, evaluated 4,368 patients with ischemic stroke or transient ischemic attack, finding that a target below 120 mmHg significantly reduced major cardiovascular events compared to standard targets, though it similarly produced more renal events, ad-hoc-news.de reported.

The MSD Manual notes that elevated blood pressure during pregnancy carries severe risks for both mother and child, including heart failure, renal insufficiency, and placental abruption, ad-hoc-news.de reported.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.